IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
07 Noviembre 2023 - 7:30AM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
DNA-mediated immunotherapy and next-generation vaccines, announces
that the Company will host a conference call at 10:00 a.m. ET on
Tuesday, November 14, 2023 to discuss financial results for the
third quarter and nine-months ended September 30, 2023 and provide
an update on its clinical development of IMNN-001, a DNA-based
interleukin-12 (IL-12) immunotherapy in Phase 2 clinical
development for the treatment of advanced-stage ovarian cancer, and
its preclinical studies of PLACCINE, a proprietary, multivalent
DNA-based plasmid technology utilizing synthetic, non-viral
delivery vectors, being evaluated in proof-of-concept studies for
superiority over current mRNA vaccines.
To participate in the call, interested parties
may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413
(International/Toll) and ask for the IMUNON Third Quarter 2023
Earnings Call. The call will also be broadcast live at
www.imunon.com. It will be archived for replay until November 28,
2023, and can be accessed at 877-344-7529 (U.S. Toll Free),
855-669-9658 (Canada Toll Free) or 412-317-0088 (International
Toll) using replay access code 7035449. An audio replay of the call
will also be available at www.imunon.com for 90 days.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas®,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas®, concerns the application of our DNA technology
to produce universal cancer vaccines, also called tumor associated
antigen cancer vaccines. The fourth modality, IndiPlas®, is in the
discovery phase and will focus on the development of personalized
cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA
virus (IMNN-102). The Company has also initiated preclinical work
to develop a Trp2 tumor associated antigen cancer vaccine in
melanoma (IMNN-201). We will continue to leverage these modalities
and to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De May 2023 a May 2024